Breast Cancer Metastasis Misdiagnosed as an Angiokeratomatous Eruption. An Infrequent Presentation. Case Report

Abstract

CT is an uncommon form of cutaneous metastasis from breast carcinoma with less than 10 cases described in the literature. There are no previous reported cases of CT mimicking angiokeratomas, although lymphangioma circumscriptum-like lesion may occasionally resemble angiokeratomas. A unique clinical presentation of CT is described.

Cutaneous metastasectomy: Is there a role in breast cancer? A systematic review and overview of current treatment modalities

“…[51][52][53] Patients with ER + disease are better suited for aromatase inhibitors, either as the initial treatment or as maintenance therapy following disease control by other systemic and local therapies. [56][57][58][59][60] Local nonsurgical therapy should be reserved for patients without visceral metastases or in extensive disease requiring symptom palliation. These include patients who have bone or cerebral metastases but also extensive drainage from their cutaneous metastases (Figure 3C).…”

“…For HER2 + breast cancer patients, trastuzumab, ado‐trastuzumab emtansine, and lapatinib have demonstrated to be effective in reducing cutaneous lesions in several case reports 51–53 . Patients with ER + disease are better suited for aromatase inhibitors, either as the initial treatment or as maintenance therapy following disease control by other systemic and local therapies 56–60 …”

“…The most commonly cited drugs were anastrozole and letrozole, which can be administered with Vitamin D or calcium supplementation, to prevent the known osteoporotic side effects 56 . In six studies, anastrozole was used as the first‐line therapy after the onset of cutaneous metastases, typically as a 1‐mg daily dose 56–60 . Alternatively, aromatase inhibitors have been used as maintenance therapy following disease control by traditional modalities such as chemotherapy, radiotherapy, and surgery.…”

“…56 In six studies, anastrozole was used as the first-line therapy after the onset of cutaneous metastases, typically as a 1-mg daily dose. [56][57][58][59][60] Alternatively, aromatase inhibitors have been used as maintenance therapy following disease control by traditional modalities such as chemotherapy, radiotherapy, and surgery. This method was reported in three case reports, which found all three patients to have partial or complete regression of their skin lesions.…”